Shares of Aurora Cannabis (NYSE: ACB) fell over 8% in morning trade on Monday as the company announced several updates from the resignation of a key executive to the rollout of Cannabis 2.0.
Aurora announced on Friday that Cam Battley stepped down from his role as Chief Corporate Officer, prompting several analysts to raise concerns about the financial health and future of the company.
On Monday, Aurora said it has been working on rationalizing capital spending, reducing debt and boosting liquidity to position itself for long-term growth. The company is expected to save approx. $200 million of cash through the deferral of certain construction and commissioning activities.
Aurora commenced shipments of initial orders received to 10 provincial regulators of Cannabis 2.0 products. New products have been made available for order by the company’s registered medical patients. Aurora will initially provide a variety of CBD and THC vape and edible products such as chocolates and mints.
Also read: Aurora Cannabis Q1 2020 Earnings Report
Aurora announced that it received approvals for its Sedamen Softgel capsules and one of its oil products in Denmark and Ireland. The company’s wholly-owned subsidiary Whistler Medical Marijuana Corp. announced the completion of the construction of its production facility in Pemberton, British Columbia.
Aurora also announced the appointment of Rick Savone as Senior Vice President of Global Government Relations. Mr. Savone will be in charge of the company’s relations with global governments and will be involved in the creation of regulations that will allow greater access to medical cannabis products for patients.
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was